Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Pepcid
Overview
What is Pepcid?
The active ingredient in PEPCID® (famotidine) is a histamine H2-receptor antagonist. Famotidine is -(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]- 4-thiazolyl]methyl]thio]propanimidamide. The empirical formula of famotidine is CHNOS and its molecular weight is 337.43. Its structural formula is:
Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol.
Each tablet for oral administration contains either 20 mg or 40 mg of famotidine and the following inactive ingredients: hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycolate, sodium starch glycolate, modified corn starch (pregelatinized starch), talc, triacetin, and titanium dioxide.
What does Pepcid look like?
What are the available doses of Pepcid?
Sorry No records found.
What should I talk to my health care provider before I take Pepcid?
Sorry No records found
How should I use Pepcid?
What interacts with Pepcid?
Sorry No Records found
What are the warnings of Pepcid?
Sorry No Records found
What are the precautions of Pepcid?
Sorry No Records found
What are the side effects of Pepcid?
Sorry No records found
What should I look out for while using Pepcid?
Hypersensitivity to any component of these products. Cross sensitivity in this class of compounds has been observed. Therefore, PEPCID should not be administered to patients with a history of hypersensitivity to other H‑receptor antagonists.
What might happen if I take too much Pepcid?
The adverse reactions in overdose cases are similar to the adverse reactions encountered in normal clinical experience (see ). Oral doses of up to 640 mg/day have been given to adult patients with pathological hypersecretory conditions with no serious adverse effects. In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed.
The oral LD of famotidine in male and female rats and mice was greater than 3000 mg/kg and the minimum lethal acute oral dose in dogs exceeded 2000 mg/kg. Famotidine did not produce overt effects at high oral doses in mice, rats, cats and dogs, but induced significant anorexia and growth depression in rabbits starting with 200 mg/kg/day orally. The intravenous LD50 of famotidine for mice and rats ranged from 254‑563 mg/kg and the minimum lethal single I.V. dose in dogs was approximately 300 mg/kg. Signs of acute intoxication in I.V. treated dogs were emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse.
How should I store and handle Pepcid?
StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. StorageStore Pantoprazole Sodium Delayed-Release Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [ ]. PEPCID Tablets, 20 mg, are white, round, film-coated tablets coded MP/973 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 40 mg, are white, round, film-coated tablets coded MP/974 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 20 mg, are white, round, film-coated tablets coded MP/973 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 40 mg, are white, round, film-coated tablets coded MP/974 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 20 mg, are white, round, film-coated tablets coded MP/973 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 40 mg, are white, round, film-coated tablets coded MP/974 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 20 mg, are white, round, film-coated tablets coded MP/973 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 40 mg, are white, round, film-coated tablets coded MP/974 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 20 mg, are white, round, film-coated tablets coded MP/973 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 40 mg, are white, round, film-coated tablets coded MP/974 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 20 mg, are white, round, film-coated tablets coded MP/973 on one side and plain on the other. They are supplied as follows: NDCNDCPEPCID Tablets, 40 mg, are white, round, film-coated tablets coded MP/974 on one side and plain on the other. They are supplied as follows: NDCNDC
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Table 6
Plasma clearance is reduced and elimination half-life is prolonged in pediatric patients 0‑3 months of age compared to older pediatric patients. The pharmacokinetic parameters for pediatric patients, ages >3 months‑15 years, are comparable to those obtained for adults.
Bioavailability studies of 8 pediatric patients (11‑15 years of age) showed a mean oral bioavailability of 0.5 compared to adult values of 0.42 to 0.49. Oral doses of 0.5 mg/kg achieved AUCs of 645 ± 249 ng hr/mL and 580 ± 60 ng‑hr/mL in pediatric patients <1 year of age (N=5) and in pediatric patients 11‑15 years of age, respectively, compared to 482 ± 181 ng‑hr/mL in adults treated with 40 mg orally.
Non-Clinical Toxicology
Hypersensitivity to any component of these products. Cross sensitivity in this class of compounds has been observed. Therefore, PEPCID should not be administered to patients with a history of hypersensitivity to other H‑receptor antagonists.No drug interactions have been identified. Studies with famotidine in man, in animal models, and have shown no significant interference with the disposition of compounds metabolized by the hepatic microsomal enzymes, e.g., cytochrome P450 system. Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine. Indocyanine green as an index of hepatic drug extraction has been tested and no significant effects have been found.
Symptomatic response to therapy with PEPCID does not preclude the presence of gastric malignancy.
The adverse reactions listed below have been reported during domestic and international clinical trials in approximately 2500 patients. In those controlled clinical trials in which PEPCID Tablets were compared to placebo, the incidence of adverse experiences in the group which received PEPCID Tablets, 40 mg at bedtime, was similar to that in the placebo group.
The following adverse reactions have been reported to occur in more than 1% of patients on therapy with PEPCID in controlled clinical trials, and may be causally related to the drug: headache (4.7%), dizziness (1.3%), constipation (1.2%) and diarrhea (1.7%).
The following other adverse reactions have been reported infrequently in clinical trials or since the drug was marketed. The relationship to therapy with PEPCID has been unclear in many cases. Within each category the adverse reactions are listed in order of decreasing severity:
Body as a Whole:
Cardiovascular:
Gastrointestinal:
Hematologic:
Hypersensitivity:
Musculoskeletal:
Nervous System/Psychiatric:
Respiratory:
Skin:
Special Senses:
Other:
The adverse reactions reported for PEPCID Tablets may also occur with PEPCID for Oral Suspension.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).